NewLimit Raises $435M to Launch First Human Trial of Longevity Liver Drug

NewLimit is one of the most closely watched startups in the longevity space, and its latest $435 million Series C raise underscores just how seriously investors are taking the field. With a valuation now sitting at $3.1 billion, the company is transitioning from preclinical research into human trials — a critical milestone that separates speculative science from validated medicine.

The company's first clinical trial will focus on a liver medicine, though the full article behind STAT+'s paywall withholds specific mechanistic or therapeutic details. The liver is a key organ in metabolic health and aging, making it a logical early target for longevity-focused interventions. Dysfunction in liver biology is linked to conditions ranging from metabolic syndrome to accelerated systemic aging.

NewLimit was co-founded by stem cell biologist Jacob Kimmel, who serves as CEO, alongside Coinbase's Brian Armstrong and former GV partner Blake Byers. The company's scientific foundation in epigenetic reprogramming — resetting aging cells toward a younger biological state — has been a central thesis since its 2021 launch. This approach, pioneered by figures like Shinya Yamanaka and David Sinclair, aims to reverse rather than merely slow biological aging.

The funding round attracted heavyweight backers: Peter Thiel's Founders Fund led the round, with participation from Thrive Capital, Lilly Ventures — the venture arm of pharmaceutical giant Eli Lilly — and tech investors Nat Friedman and Daniel Gross. Lilly's involvement is particularly notable, suggesting potential pharmaceutical partnership pathways.

For health-conscious observers, this signals that epigenetic reprogramming therapies may be closer to clinical reality than previously assumed. However, clinical trials are lengthy, and early-phase trials primarily test safety rather than efficacy. Meaningful human outcome data remains years away, and commercial availability further still.